Bcl-xL, overexpressed in human lung adenocarcinoma (ACL), is an ideal target for antisense therapy

被引：0
|
作者：
Li, E
Xiao, H
Vikram, B
机构：
[1] NYU Med Ctr, New York, NY 10016 USA
[2] Montefiore Med Ctr, Bronx, NY 10467 USA
来源：
MODERN PATHOLOGY | 2001年 / 14卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
1313
引用
收藏
页码：223A / 223A
页数：1
相关论文
共 50 条
  • [41] Bcl-xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts
    Littlejohn, James E.
    Cao, Xiaobo
    Miller, Steven D.
    Ozvaran, Mustafa K.
    Jupiter, Daniel
    Zhang, Lidong
    Rodarte, Charles
    Smythe, W. Roy
    INTERNATIONAL JOURNAL OF CANCER, 2008, 123 (01) : 202 - 208
  • [42] The importance of Bcl-XL in the survival of human RPE cells
    Zhang, Nanfei
    Peairs, James J.
    Yang, Ping
    Tyrrell, Jillian
    Roberts, Jennifer
    Kole, Ryszard
    Jaffe, Glenn J.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2007, 48 (08) : 3846 - 3853
  • [43] Optimizing chemotherapy for transitional cell carcinoma by application of bcl-2 and bcl-xL antisense oligodeoxynucleotides
    Bolenz, Christian
    Becker, Andreas
    Trojan, Lutz
    Schaaf, Axel
    Cao, Yanwei
    Weiss, Christel
    Alken, Peter
    Michel, Maurice Stephan
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2007, 25 (06) : 476 - 482
  • [44] Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity
    Del Bufalo, D
    Trisciuoglio, D
    Scarsella, M
    Zangemeister-Wittke, U
    Zupi, G
    ONCOGENE, 2003, 22 (52) : 8441 - 8447
  • [45] Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity
    Donatella Del Bufalo
    Daniela Trisciuoglio
    Marco Scarsella
    Uwe Zangemeister-Wittke
    Gabriella Zupi
    Oncogene, 2003, 22 : 8441 - 8447
  • [46] P53-independent induction of apoptosis in human melanoma cells by a bcl-2/bcl-xL bispecific antisense oligonucleotide
    Rieber, MS
    Zangemeister-Wittke, U
    Rieber, M
    CLINICAL CANCER RESEARCH, 2001, 7 (05) : 1446 - 1451
  • [47] Bcl-xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms
    Petiti, Jessica
    Lo Iacono, Marco
    Rosso, Valentina
    Andreani, Giacomo
    Jovanovski, Aleksandar
    Podesta, Marina
    Lame, Dorela
    De Gobbi, Marco
    Fava, Carmen
    Saglio, Giuseppe
    Frassoni, Francesco
    Cilloni, Daniela
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2020, 24 (18) : 10978 - 10986
  • [48] Correction: BCL-XL is an actionable target for treatment of malignant pleural mesothelioma
    Surein Arulananda
    Megan O’Brien
    Marco Evangelista
    Tiffany J. Harris
    Nikita S. Steinohrt
    Laura J. Jenkins
    Marzena Walkiewicz
    Robert J. J. O’Donoghue
    Ashleigh R. Poh
    Bibhusal Thapa
    David S. Williams
    Trishe Leong
    John M. Mariadason
    Xia Li
    Jonathan Cebon
    Erinna F. Lee
    Thomas John
    W. Douglas Fairlie
    Cell Death Discovery, 7
  • [49] Antisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma
    Ozvaran, MK
    Cao, XBX
    Miller, SD
    Monia, BA
    Hong, WK
    Smythe, WR
    MOLECULAR CANCER THERAPEUTICS, 2004, 3 (05) : 545 - 550
  • [50] Treatment of melanoma cells with bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity.
    Del Bufalo, D
    Trisciuoglio, D
    Scarsella, M
    Zandemeister-Wittke, U
    Zupi, G
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6145S - 6145S
12345